Press Releases Year None202120202019201820172015 September 21, 2021 ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor September 1, 2021 ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences August 16, 2021 ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors August 10, 2021 ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update June 28, 2021 ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor June 2, 2021 ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel May 26, 2021 ORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference May 25, 2021 ORIC Pharmaceuticals to Host Conference Call with KOL to Review Initial Data Being Presented at ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel May 6, 2021 ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update April 28, 2021 ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 17
